MYGN Myriad Genetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MYGN

Price (delayed)

$3.17

Market cap

$303.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.18

Enterprise value

$398.51M

?
Relative Growth: Rel. Growth: 37
Relative Strength: Rel. Strength: 9
Relative Valuation: Rel. Valuation: 37
Relative Profitability: Rel. Profitability: 40

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the ...

Highlights
The company's net income has surged by 72% QoQ and by 72% YoY
The EPS has soared by 72% from the previous quarter and by 72% YoY
The quick ratio has soared by 62% year-on-year but it has declined by 10% since the previous quarter
The debt has grown by 36% YoY
The company's equity fell by 22% YoY and by 10% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://myriad.com
Peers: BMRN BIO ABT

Key stats

What are the main financial stats of MYGN

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
-1.86%
1 week
-0.31%
1 month
-45.9%
1 year
-46%
YTD
-48.46%
QTD
-44.48%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$806.6M
Gross profit
$555.2M
Operating income
-$98.6M
Net income
-$112.6M
Gross margin
68.8%
Net margin
-14%
The company's operating margin has surged by 76% YoY and by 74% QoQ
The operating income has soared by 76% YoY and by 75% QoQ
The company's net income has surged by 72% QoQ and by 72% YoY
The net margin has soared by 71% from the previous quarter and by 70% YoY

Price vs fundamentals

How does MYGN's price correlate with its fundamentals

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
0.99
P/S
0.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.49
The EPS has soared by 72% from the previous quarter and by 72% YoY
MYGN's price to book (P/B) is 51% lower than its 5-year quarterly average of 2.0 and 38% lower than its last 4 quarters average of 1.6
The company's equity fell by 22% YoY and by 10% QoQ
The P/S is 82% lower than the 5-year quarterly average of 2.0 and 47% lower than the last 4 quarters average of 0.7
Myriad Genetics's revenue has decreased by 3.2% YoY and by 2.7% QoQ

Efficiency

How efficient is Myriad Genetics business performance
The return on invested capital has surged by 81% year-on-year and by 77% since the previous quarter
The ROS has soared by 76% YoY and by 75% from the previous quarter
Myriad Genetics's return on assets has surged by 71% QoQ and by 61% YoY
MYGN's return on equity has surged by 70% since the previous quarter and by 48% year-on-year

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
Myriad Genetics's total assets is 91% more than its total liabilities
The quick ratio has soared by 62% year-on-year but it has declined by 10% since the previous quarter
Myriad Genetics's current ratio has soared by 56% YoY but it has decreased by 8% from the previous quarter
The debt is 31% less than the equity
The debt to equity has soared by 73% year-on-year and by 10% since the previous quarter
The debt has grown by 36% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.